OCUPHIRE PHARMA INC (OCUP)
US67577R1023 - Common Stock
What's going on in today's after hours session
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 ...
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on...
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023
OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocuphire Pharma (NASDAQ:OCUP) just reported results for the fourth quarter of 2...
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on...
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic...
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma appointed Nirav Jhaveri as CFO (NASDAQ:OCUP)
Ocuphire Pharma strengthens leadership team with the appointment of Nirav Jhaveri as CFO and Ash Jayagopal as Chief Scientific and Development Officer.
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer ...
3 Value Stocks to Buy on the Dip: February 2024
While many investors continue to chase after the latest trends, these underappreciated value stocks to buy could be the true winners.
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma files for a $175M mixed securities shelf (NASDAQ:OCUP)
Ocuphire Pharma (OCUP) files prospectus for a mixed shelf offering, aiming to raise up to $175M; not an offer to sell securities.
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024...
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023...
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside.
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire announces appointment of Joseph Schachle as chief operating officer (NASDAQ:OCUP)
Ocuphire Pharma appoints Joseph Schachle as chief operating officer, signaling strategic expansion for the advancement of their lead retina asset.
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial...
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI™ Approved by FDA; Ocuphire Received $10...
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma appoints George Magrath as CEO (NASDAQ:OCUP)
Ocuphire Pharma announces George Magrath as new CEO, replacing interim chief Rick Rodgers.
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development...
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy...
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.,
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024...
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
FARMINGTON HILLS, Mich., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that company management will be participating in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City on September 11-13, 2023. Additionally, Ronil Patel, MS, Ocuphire’s SVP of Operations & Business Development, will be participating in panel presentations at both the Cantor Annual Global Healthcare Conference being held in New York City on September 26-28, 2023 and the Inaugural Jones Trading 2023 Healthcare Summit being held in Miami Beach on October 9-11, 2023.
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of...
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Million Expected to Fund...
Surprise! These 3 Penny Stocks Pack Powerful Financials.
While investing in penny stocks carries a rough reputation (to put it nicely), these speculative entities just might surprise you.
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., July 10, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its...
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
FARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its...